Cancer Gene Therapy (Animal Models)

Local Interferon Engineered by Gene Transfer Safely Halts Malignant Mesothelioma

Published in Gene Therapy Weekly, October 18th, 1999

Locally produced interferon, engineered by gene-transfer methods, can prevent tumor growth in a mouse model of human malignant mesothelioma without causing any obvious side effects, according to research published in the September 1999 issue of the American Journal of Respiratory Cell and Molecular Biology.

Malignant mesothelioma (MM) is an aggressive tumor of the mesothelial lining of the pleura - the delicate membrane covering the lungs and the inner surface of the chest. The cancer is associated with prior exposure to asbestos and is latent for 15 to 40 years. The average survival time for victims following diagnosis is nine months. To date, neither surgery,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1999-10-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry